S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01

Vascular Biogenics Stock Forecast, Price & News

+0.06 (+3.66%)
(As of 01/14/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
421,505 shs
Average Volume
204,628 shs
Market Capitalization
$106.03 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive VBLT News and Ratings via Email

Sign-up to receive the latest news and ratings for Vascular Biogenics and its competitors with MarketBeat's FREE daily newsletter.

Vascular Biogenics logo

About Vascular Biogenics

Vascular Biogenics Ltd. is in the clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of first-in-class treatments for cancer. Its programs include cancer, inflammation, and VB-600 which are focused on treating tumors, ovarian cancer, and chronic immune-related indications. The company was founded by Dror Harats and Jacob George on January 27, 2000 and is headquartered in Modi'in, Israel.


BridgeBio (BBIO) Tumbles on Cardiomyopathy Candidate Failure
December 28, 2021 |  finance.yahoo.com
What Makes Vascular Biogenics (VBLT) a New Buy Stock
November 18, 2021 |  finance.yahoo.com
Vascular Biogenics earnings preview: what Wall Street is expecting
November 15, 2021 |  markets.businessinsider.com
VBL Therapeutics to Present at Upcoming Conferences
September 10, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Previous Symbol
Year Founded

Sales & Book Value

Annual Sales
$920 thousand
Book Value
$0.64 per share


Net Income
$-24.23 million
Net Margins
Pretax Margin




Free Float
Market Cap
$106.03 million

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

1.68 out of 5 stars

Medical Sector

974th out of 1,410 stocks

Pharmaceutical Preparations Industry

473rd out of 680 stocks

Analyst Opinion: 3.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Vascular Biogenics (NASDAQ:VBLT) Frequently Asked Questions

Is Vascular Biogenics a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vascular Biogenics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Vascular Biogenics stock.
View analyst ratings for Vascular Biogenics
or view top-rated stocks.

How has Vascular Biogenics' stock price been impacted by Coronavirus (COVID-19)?

Vascular Biogenics' stock was trading at $1.22 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, VBLT stock has increased by 39.3% and is now trading at $1.70.
View which stocks have been most impacted by COVID-19

Are investors shorting Vascular Biogenics?

Vascular Biogenics saw a drop in short interest in December. As of December 31st, there was short interest totaling 1,630,000 shares, a drop of 20.9% from the December 15th total of 2,060,000 shares. Based on an average trading volume of 201,800 shares, the days-to-cover ratio is presently 8.1 days.
View Vascular Biogenics' Short Interest

When is Vascular Biogenics' next earnings date?

Vascular Biogenics is scheduled to release its next quarterly earnings announcement on Thursday, March 24th 2022.
View our earnings forecast for Vascular Biogenics

How were Vascular Biogenics' earnings last quarter?

Vascular Biogenics Ltd. (NASDAQ:VBLT) issued its quarterly earnings data on Monday, November, 15th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, beating analysts' consensus estimates of ($0.11) by $0.02. The biopharmaceutical company had revenue of $0.20 million for the quarter, compared to the consensus estimate of $0.20 million. Vascular Biogenics had a negative trailing twelve-month return on equity of 66.02% and a negative net margin of 3,612.61%. During the same period in the prior year, the firm earned ($0.12) earnings per share.
View Vascular Biogenics' earnings history

What price target have analysts set for VBLT?

4 equities research analysts have issued 12-month target prices for Vascular Biogenics' stock. Their forecasts range from $4.00 to $7.00. On average, they anticipate Vascular Biogenics' share price to reach $5.75 in the next twelve months. This suggests a possible upside of 238.2% from the stock's current price.
View analysts' price targets for Vascular Biogenics
or view top-rated stocks among Wall Street analysts.

Who are Vascular Biogenics' key executives?

Vascular Biogenics' management team includes the following people:
  • Dror Harats, Chief Executive Officer & Director
  • Eyal Breitbart, Vice President-Research & Operations
  • Erez Feige, Vice President-Business Operations
  • Samuel I. Backenroth, Chief Financial Officer
  • Tami Rachmilewitz, Vice President-Clinical Development

What other stocks do shareholders of Vascular Biogenics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vascular Biogenics investors own include SCYNEXIS (SCYX), Matinas BioPharma (MTNB), OPKO Health (OPK), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Aeterna Zentaris (AEZS), Dynavax Technologies (DVAX), Vaxart (VXRT) and Geron (GERN).

What is Vascular Biogenics' stock symbol?

Vascular Biogenics trades on the NASDAQ under the ticker symbol "VBLT."

How do I buy shares of Vascular Biogenics?

Shares of VBLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vascular Biogenics' stock price today?

One share of VBLT stock can currently be purchased for approximately $1.70.

How much money does Vascular Biogenics make?

Vascular Biogenics has a market capitalization of $106.03 million and generates $920 thousand in revenue each year. The biopharmaceutical company earns $-24.23 million in net income (profit) each year or ($0.48) on an earnings per share basis.

How many employees does Vascular Biogenics have?

Vascular Biogenics employs 38 workers across the globe.

What is Vascular Biogenics' official website?

The official website for Vascular Biogenics is www.vblrx.com.

Where are Vascular Biogenics' headquarters?

Vascular Biogenics is headquartered at 8 HASATAT STREET, MODI IN L3, 7178106.

How can I contact Vascular Biogenics?

Vascular Biogenics' mailing address is 8 HASATAT STREET, MODI IN L3, 7178106. The biopharmaceutical company can be reached via phone at (728) 993-5000, via email at [email protected], or via fax at 972-8993-5001.

This page was last updated on 1/16/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.